Study title: The long-term safety and efficacy of Risperdal® in conduct disorder in mild, moderate and borderline mentally retarded children aged 5 to 14 years.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Behavior and Behavior Mechanisms | |||||
Brands: Please see report, Please see report | |||||
MAH holders: Please see report, Please see report | |||||
Assessment: | |||||
Active substance: RISPERIDONE | |||||
ATC code: | |||||
Document link: | |||||
Document date: | |||||
Study number: 3003 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |